Bio Pharma Dive
JULY 26, 2022
New companies are being built more carefully and platform technologies are less in vouge as the downturn's effects ripple through the private sector.
Pharmaceutical Technology
JULY 26, 2022
According to GlobalData’s recent Niemann-Pick Type C (NPC): Opportunity Analysis and Forecast to 2031 report, the NPC market is expected to see significant growth during 2021–31. The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JULY 26, 2022
Quick Read: Amazon will dramatically expand its healthcare reach with its planned $3.9 billion acquisition of One Medical, a primary care provider with 188 offices in 25 markets nationwide but are they making a strategic move or a mistake? Telehealth has a future, but one could argue that physicians need to see patients firsthand to diagnose and evaluate patients.
NPR Health - Shots
JULY 28, 2022
Dr. Dimie Ogoina detected monkeypox in an 11-year-old patient in 2017 and saw many other cases since. He's tried to warn health officials that the virus has changed the way it spreads — to no avail. (Image credit: Dr.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
JULY 27, 2022
The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO.
Pharmaceutical Technology
JULY 25, 2022
With decreasing margins on the horizon, pharma manufacturers have long shown an interest in specialty generics, which is only expected to rise in the future. Despite this, specialty generics are expected to be the domain of a handful of companies with the necessary manufacturing capabilities and legal backing needed for entering the market. Specialty generics is a term used to refer to generic versions of drugs that are often expensive, complex, or “high touch”—requiring significant involvement
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
NPR Health - Shots
JULY 28, 2022
Debt lawsuits — a byproduct of America's medical debt crisis — can ensnare not only patients but also those who help sick and older people be admitted to nursing homes, a KHN-NPR investigation finds.
Bio Pharma Dive
JULY 26, 2022
Three startups have recently emerged with plans to edit the epigenome rather than DNA directly. Here’s why that matters and what they aim to do.
Pharmaceutical Technology
JULY 25, 2022
The COVID-19 pandemic triggered significant changes to the way healthcare operates. Digitalization is now in full swing as medical care integrates with ICT to take the patient experience to the next level. According to Tom Lenaerts, Head of Global Process Engineering at Datwyler, this transformation will reshape the entire healthcare ecosystem. “There are already opportunities for patients to track their health through smart medical devices sending reports directly to their healthcare provider.
STAT News
JULY 26, 2022
Almost two years have passed since Dean Fritzemeier fell ill with Covid in October 2020. As the rest of the world moves on, shrugging off new variants and traveling with a vengeance, he remains trapped in a life weighed down by the virus. Fritzemeier is always tired, but can’t sleep. The 52-year-old once walked 7 miles a day, but now can only get outside if he’s pushed in a wheelchair.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
NPR Health - Shots
JULY 24, 2022
The World Health Organization has declared monkeypox a public health emergency of global concern. From how it spreads to preventive measures, here's what you need to know about the disease.
Bio Pharma Dive
JULY 26, 2022
Known as tofersen, the drug failed in the main study being used to support its approval. But an apparent effect on a protein of interest in ALS research has Biogen convinced the treatment will pass muster with regulators.
Pharmaceutical Technology
JULY 29, 2022
Pfizer has reported a 53% operational growth in revenues to $27.7bn in the second quarter (Q2) of 2022 compared to $18.9bn in the same quarter last year. The rise in revenues was chiefly driven by robust contributions from Covid-19 therapies Paxlovid and Comirnaty. On an operational basis, the revenues rose by $128m or 1%, excluding Paxlovid and Comirnaty’s contributions.
Pharma Times
JULY 28, 2022
The British Heart Foundation’s ‘Big Beat Challenge’ grant of £30m for research into cardiovascular medicine was given to CureHeart
NPR Health - Shots
JULY 28, 2022
Evusheld, a course of injected antibodies, helps protect people with weak immune systems for up to six months. The government is making it available through pharmacies and individual providers.
Bio Pharma Dive
JULY 25, 2022
The agency agreed to quickly assess the companies’ drug Enhertu for “HER2 low” metastatic breast cancer, an indication for which it could become the first targeted treatment option.
Pharmaceutical Technology
JULY 29, 2022
The Food and Drug Administration (FDA) has acc epted to review ImmunityBio’s Biologics License Application (BLA) for N-803 to treat Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients with or without Ta or T1 disease. A decision from the regulatory agency on approval for the treatment is anticipated on 23 May next year.
Rethinking Clinical Trials
JULY 27, 2022
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?. Speaker. Susanna Naggie, MD, MHS. Professor of Medicine. Vice Dean for Clinical Research. Duke University School of Medicine. Slides. Keywords. ACTIV, ACTIV-6, COVID-19, Ivermectin, Inhaled Fluticasone. Key Points. The key clinical questions of the ACTIV-6 study are: how to help someone feel better faster with newly diagnosed mild-moderate COVID-19 and how to prevent hospitalizations or death in someone with n
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
JULY 26, 2022
Newly diagnosed cancer patients across the UK will get free access to digital mental health therapies, thanks to a new partnership between Macmillan Cancer Support and Big Health. The alliance, billed as the first of its kind in the UK, means that cancer patients will be able to use Big Health apps like Sleepio and Daylight, which aim to treat insomnia and anxiety using cognitive behavioural therapy (CBT) techniques.
Bio Pharma Dive
JULY 28, 2022
The company plans to ready a booster shot by the fall that targets the BA.4 and BA.5 strains that are currently most prevalent in the U.S. and other countries.
Pharmaceutical Technology
JULY 29, 2022
The rate at which children are being identified with autism spectrum disorder (ASD) has tripled in the past two decades. While the prevalence was 1 in 150 children in 2000, it reached the rate of 1 in 44 in 2018, in the US, according to the Centers for Disease Control and Prevention. Some people with ASD can experience acute agitation and crisis behaviours.
NPR Health - Shots
JULY 25, 2022
Cases in the U.S. are 10 times higher than they were a month ago. Researchers advise that the coming days and weeks will be crucial as to whether the outbreak can be contained.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
STAT News
JULY 26, 2022
The value-based payment crusade is now two decades old. But despite the tens of billions of dollars — perhaps hundreds of billions — spent on these programs, they have done little to improve Americans’ health or lower health care costs. It is time for proponents of value-based care to call a halt to these programs until they have an answer to this question: “Why have the vast majority of value-based payment experiments failed to improve value?
Bio Pharma Dive
JULY 29, 2022
Health officials are gearing up for a fall vaccination campaign and aim to deploy shots modified to better match circulating omicron subvariants.
Pharmaceutical Technology
JULY 28, 2022
Bristol Myers Squibb (BMS) has reported a 2% rise in revenues to $11.9bn in the second quarter (Q2) of 2022 compared to $11.7bn in Q2 last year. The revenue growth was driven by in-line products, mainly Eliquis and Opdivo, as well as the company’s latest product portfolio comprising Abecma, Opdualag and Reblozyl. New LOE products, especially Revlimid and foreign exchange, impacts partially offset the increase in revenues.
Pharma Times
JULY 27, 2022
First carbon minimal pMDI is on track with the joint goal of benefitting patients and the planet
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Marketing Network
JULY 27, 2022
In the first two weeks after a cancer diagnosis, there are likely dozens of doctor’s visits, tests, consultations, and decision points. The patient care team supplies an abundance of information, although sifting through brochures and online resources can be daunting for the patient and their caregiver. Adhering to regulatory guidelines is an important step pharma takes to ensure that promotional medical materials contain balanced information that is accurate and relevant. 1 The marketer’s goal
Bio Pharma Dive
JULY 26, 2022
The mid-stage trial tested the companies’ drug Padcev with Merck’s Keytruda in first-line bladder cancer. The data are reportedly a factor in Merck’s talks with Seagen over a potential buyout.
Pharmaceutical Technology
JULY 27, 2022
The US Food and Drug Administration (FDA) has granted priority review for Biogen ’s New Drug Application (NDA) for investigational drug, tofersen, to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). A decision from the regulatory agency on approval for the drug is anticipated on 25 January next year. The FDA also plans to hold an advisory committee meeting for the NDA.
Pharma Times
JULY 26, 2022
Funding will develop inhaled therapies using ICOone Nasal in preparation for the next pandemic
Expert insights. Personalized for you.
361 
Let's personalize your content